Malignant neoplasm of breast
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer
Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo
Eli Lilly Acquires Scorpion Therapeutics in $2.5 Billion Deal to Boost Breast Cancer Treatment Options
Eli Lilly, Scorpion Therapeutics, breast cancer, PI3Kα inhibitor, STX-478, oncology pipeline, targeted therapy
Elinzanetant Shows Promise in Reducing Hot Flashes in Women Undergoing Breast Cancer Therapy
Elinzanetant, Vasomotor Symptoms, Breast Cancer, Adjuvant Endocrine Therapy, Hot Flashes, Non-Hormonal Treatment
Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer
Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor
Relay Therapeutics Advances PI3K Inhibitor for Breast Cancer Subgroup with Promising Early Trial Results
Relay Therapeutics, PI3K inhibitor, breast cancer, RLY-2608, metastatic breast cancer, PI3Ka mutations, clinical trial
BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results
BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies
Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials
Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)
Olema Secures $250 Million Funding for Pivotal Breast Cancer Trial Featuring Novartis’ Kisqali
Olema, Breast Cancer, Novartis, Kisqali, Pivotal Trial, Funding
NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England